The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. For more information, visit Forward-Looking StatementsĪll statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's proposed Offering. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. ![]() is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, and other rare neurological disorders. The final prospectus will be filed with the SEC and will be available on the SEC’s website at Copies of the final prospectus, when available, may be obtained from Laidlaw & Company (UK) Ltd., 521 Fifth Ave., 12th Floor, New York, NY 10175, Attention: Syndicate Dept. 333-261532) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on September 15, 2022. is acting as sole book-running manager for the offering.Ī registration statement on Form S-1 (File No. The offering is expected to close on or about September 29, 2022, subject to customary closing conditions. In addition, the Company has granted a 45-day option to the underwriter to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any. A portion of the proceeds may also be used for acquisitions of complementary businesses, technologies, or other assets.Īs a result of the offering, the Company’s common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol “SILO” beginning September 27, 2022. Silo Pharma intends to use the net proceeds from the offering for product development, marketing, and working capital and general corporate purposes. Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of 5 Million Public Offering of Common Stock. The gross proceeds to Silo Pharma from this offering are expected to be $5,000,000, before deducting the underwriting discount and other estimated offering expenses payable by Silo Pharma. Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. ![]() 27, 2022 (GLOBE NEWSWIRE) - Silo Pharma, Inc. Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO”ĮNGLEWOOD CLIFFS, NJ, Sept.
0 Comments
Leave a Reply. |